Patents Issued in May 11, 2017
-
Publication number: 20170130202Abstract: The present invention aims to provide a novel method for producing mesodermal cells, and a graft material containing mesodermal cells obtained by this method. The present invention also aims to provide a novel method for producing hematopoietic cells, and a therapeutic agent for blood diseases containing a hematopoietic cell obtained by the method. These objects can be achieved by providing a novel method for producing mesodermal cells and/or hematopoietic cells, which method includes culturing pluripotent stem cells in contact with a three-dimensional support.Type: ApplicationFiled: June 24, 2015Publication date: May 11, 2017Inventors: Tatsutoshi Nakahata, Megumu Saito, Akira Niwa, Yoshinori Sugimine
-
Publication number: 20170130203Abstract: The present invention is a method for culturing adherent cells that can allow adherent cells to survive and grow even in a suspended state, a culture vessel that is formed using an alicyclic structure-containing polymer, and includes a liquid medium, and adherent cells that survive in the liquid medium in a suspended state, and a method for producing a protein. The adhesive cells can be grown in a method for culturing adherent cells comprising bringing adherent cells into contact with an alicyclic structure-containing polymer formed article to grow the adherent cells in a state in which the adherent cells are suspended in a liquid medium.Type: ApplicationFiled: June 24, 2015Publication date: May 11, 2017Applicant: ZEON CORPORATIONInventors: Naoya ICHIMURA, Takaaki HIRANO
-
Publication number: 20170130204Abstract: The present invention relates to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell and a use thereof and, more specifically, to a composition for inducing direct transdifferentiation of a somatic cell into a vascular progenitor cell, a pharmaceutical composition for the prevention or treatment of ischemic vascular diseases, a cell therapeutic agent for the prevention or treatment of ischemic vascular diseases, a composition for screening a therapeutic drug for ischemic vascular diseases, a 3D printing biological material composition for the production of an artificial tissue for the treatment of ischemic vascular diseases, and a method for direct transdifferentiation of a somatic cell into a vascular progenitor cell.Type: ApplicationFiled: March 3, 2015Publication date: May 11, 2017Applicant: UNIST(Ulsan National Institute of Science and Techology)Inventor: Jeong Beom KIM
-
Publication number: 20170130205Abstract: The present invention relates to a novel method for preparing induced pluripotent stem cells (iPSCs) by introducing four genes, Oct-4, Sox2, Klf4, and Glial, into somatic cells. The present invention also relates to the iPSCs produced by the aforementioned method. Also provided is a process of drug selection for a heritable genetic disease by use of the iPSCs produced by the aforementioned method. In particular, wherein the inherited disease is Fabry disease. The present invention also relates to a method for treating Fabry-associated myocardiopathy in a subject in need thereof, and a method for determining prognosis in a subject with Fabry-associated myocardiopathy.Type: ApplicationFiled: November 23, 2015Publication date: May 11, 2017Inventor: SHIH-HWA CHIOU
-
Publication number: 20170130206Abstract: Provided are a novel hemagglutinin that can remove cells deviated from the undifferentiated state, the cells being cells that emerge in a colony during culture of stem cells having pluripotency, and a novel method for culturing stem cells having pluripotency, the method using hemagglutinin. Provided is a mutant hemagglutinin complex protein derived from Clostridium botulinum type B, the complex protein containing at least subcomponents HA2 and HA3 of hemagglutinin derived from Clostridium botulinum type B, and the complex protein containing amino acids constituting a glycosylation site, with at least one of the amino acids having been mutated. Provided is a method for culturing stem cells having pluripotency, the method including culturing the stem cell having pluriopotency in the presence of a mutant hemagglutinin complex protein of the present disclosure.Type: ApplicationFiled: June 29, 2015Publication date: May 11, 2017Applicant: Osaka UniversityInventors: Masahiro Kinooka, Meehae Kim, Yukako Fujinaga, Yo Sugawara
-
Publication number: 20170130207Abstract: This disclosure provides isolated infectious polynucleotides, such as infectious clones, having a nucleotide sequence with identity to PRRS viruses such as VR-2332, Lelystad, or others, and optionally further including a deletion in a region of ORF1 that encodes the nsp2 polypeptide.Type: ApplicationFiled: July 8, 2015Publication date: May 11, 2017Inventors: Kay Faaberg, Jun Han, Gongping Liu, Yue Wang
-
Publication number: 20170130208Abstract: Provided herein are compositions and methods related to purification of recombinant adeno-associated virus (rAAV) particles.Type: ApplicationFiled: July 2, 2015Publication date: May 11, 2017Applicant: University of Florida Research Foundation, Inc.Inventors: Mark R. Potter, Barry John Byrne
-
Publication number: 20170130209Abstract: The present invention relates to a recombinant microbial host for the production of xylitol, the recombinant microbial host containing a nucleic acid sequence encoding an NAD+-specific D-arabitol 4-oxidoreductase (EC 1.1.1.11) using D-arabitol as substrate and producing D-xylulose as product, and a nucleic acid sequence encoding an NADPH-specific xylitol dehydrogenase using D-xylulose as substrate and producing xylitol as product.Type: ApplicationFiled: June 17, 2015Publication date: May 11, 2017Inventors: ASTRID SCHAEFER, MELANIE DIEFENBACHER, YIMING CHANG, SUMIRE HONDA MALCA, MARKUS SCHWAB, SOPHIE DEFRETIN, TANIA GERARD, ARNAUD HEYSEN, FRIEDERIKE THOR
-
Publication number: 20170130210Abstract: Described herein are methods for dynamic redirection of metabolic flux in a cell from central metabolism towards production of heterologous products.Type: ApplicationFiled: June 9, 2015Publication date: May 11, 2017Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGYInventors: Irene Marie BROCKMAN, Kristala Lanett Jones PRATHER, Apoorv GUPTA
-
COMPOSITIONS AND METHODS FOR BIOLOGICAL PRODUCTION OF AMINO ACIDS IN HYDROGENOTROPHIC MICROORGANISMS
Publication number: 20170130211Abstract: The present disclosure provides compositions and methods for using hydrogenotrophic microorganisms capable of biologically utilizing or converting H2 and CO and/or CO2 gas into high-value molecules and biological material, such as essential amino acids (e.g., lysine, threonine, methionine) and animal feed.Type: ApplicationFiled: January 2, 2015Publication date: May 11, 2017Inventors: Jill Bradshaw, Zhihao Hu, Jay Kouba -
Publication number: 20170130212Abstract: The present invention relates to a method for preparing an expression vector encoding a tailored recombinase, which tailored recombinase is capable of recombining asymmetric target sequences within the long terminal repeat (LTR) of proviral DNA of a plurality of retrovirus strains inserted into the genome of a host cell, as well as to the obtained expression vector, cells transfected with this, expressed recombinase and pharmaceutical compositions comprising the expression vector, cells and/or recombinase. Pharmaceutical compositions are useful, e.g., in treatment and/or prevention of retrovirus infection. In particular, asymmetric target sequences present in a plurality of HIV strains are disclosed, as well as tailored recombinases capable of combining these sequences (Tre 3.0 and 4.0) and expression vectors encoding them.Type: ApplicationFiled: November 10, 2016Publication date: May 11, 2017Inventors: Joachim Hauber, Jan Chemnitz, Frank Buchholz, Janet Chusainow
-
Publication number: 20170130213Abstract: This invention refers to the obtainment of a modified lipolytic enzyme that was isolated, expressed and purified from the heterologous expression. The gene sequence that codifies for the basal enzyme was obtained based on a thermo acidophilus organism of the acidobacteraceae family. This basal enzyme that comes from a thermo acidophilus organism, it is able to hydrolyze lipid substrates (triacylglycerols) united to middle chain fatty acids (C6-C10) such as tributyrine and tricapryln, among others. It also can carry out other inverse reactions to the hydrolysis such as synthesis reactions. On the other hand, this enzyme has enantioselective preference on (S) substrates of profens esters such as ibuprofen, naproxen and others. The enantioselective lipolytic basal enzyme was modified in its terminal C end to add an amino acid histidine tail that gives a higher efficiency in its purification process.Type: ApplicationFiled: April 30, 2015Publication date: May 11, 2017Applicants: CORPORACIÓN CORPOGEN, PONTIFICIA UNIVERSIDAD JAVERIANAInventors: María Mercedes ZAMBRANO EDER, Sandra BAENA GARZÓN, Gina Pilar LÓPEZ RAMÍREZ
-
Publication number: 20170130214Abstract: Acinetobacter lysin polypeptides and variants peptides with killing activity against gram negative bacteria. Methods for treating bacterial infections or bacterial colonization using Acinetobacter lysin polypeptides.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Applicant: The Rockefeller UniversityInventors: Vincent Fischetti, Raymond Schuch, Rolf Lood, Benjamin Winer
-
Publication number: 20170130215Abstract: The invention relates to polypeptides having glucanase, e.g., endoglucanase, mannanase, xylanase activity or a combination of these activities, and polynucleotides encoding them. In one aspect, the glucanase activity is an endoglucanase activity (e.g., endo-1,4-beta-D-glucan 4-glucano hydrolase activity) and comprises hydrolysis of 1,4 -beta-D-glycosidic linkages in cellulose, cellulose derivatives (e.g., carboxy methyl cellulose and hydroxy ethyl cellulose) lichenin, beta-1,4 bonds in mixed beta-1,3 glucans, such as cereal beta-D-glucans or xyloglucans and other plant material containing cellulosic parts. In addition, methods of designing new enzymes and methods of use thereof are also provided. In alternative aspects, the new glucanases e.g., endoglucanases, mannanases, xylanases have increased activity and stability at increased pH and temperature.Type: ApplicationFiled: July 25, 2016Publication date: May 11, 2017Inventors: Brian Steer, Walter Niles Callen, Shaun Healey, Derrick Pulliam
-
Publication number: 20170130216Abstract: The present disclosure provides for compositions comprising a chimeric polypeptide comprising a polypeptide effective for treating glycogen storage disease and an internalizing moiety that promotes delivery into cells. In certain embodiments, the polypeptide effective for treating glycogen storage disease is an acid alpha-glucosidase (GAA), a laforin, an amyloglucosidase (AGL), a malin, or an alpha amylase. The present disclosure also provides for methods for decreasing glycogen accumulation in cells or for treating glycogen storage diseases, including Forbes-Cori Disease, Andersen Disease, von Gierke Disease, Pompe Disease, and Lafora Disease, comprising administering the chimeric polypeptide disclosed herein.Type: ApplicationFiled: June 12, 2015Publication date: May 11, 2017Inventor: Dustin D. Armstrong
-
Publication number: 20170130217Abstract: The present invention provides a ?-agarase, a composition containing the same and applications thereof. The present ?-agarase provides the field a novel alternative and is favorable for the industrial utilities of the hydrolysis products of agarose. Furthermore, the hydrolysis product of agarose by the present ?-agarase has high purity of neoagarotetraose therefore the present ?-agarase is especially useful for the neoagarotetraose's utilities in the field.Type: ApplicationFiled: July 25, 2016Publication date: May 11, 2017Applicant: AGRICULTURAL TECHNOLOGY RESEARCH INSTITUTEInventors: Jiunn-Horng LIN, Jyh-Perng WANG, Zeng-Weng CHEN, Hui-Jie LIN, Weng-Zeng HUANG, Jian-Fong LAI, Shih-Ling HSUAN
-
Publication number: 20170130218Abstract: A method for selecting and isolating aptamers that target M-Ig proteins with a microdevice including at least a first selection chamber is provided. The method includes preparing a first sample of M-Ig proteins from a serum; placing the M-Ig proteins in the first selection chamber; introducing a first group of oligomers including at least an M-Ig targeting oligomer into the first selection chamber, whereby the M-Ig targeting oligomer binds to the first sample of M-Ig proteins. The method further includes removing unbound oligomers of the first sample from the first selection chamber to isolate the M-Ig targeting oligomer.Type: ApplicationFiled: January 24, 2017Publication date: May 11, 2017Applicant: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORKInventor: Qiao Lin
-
Publication number: 20170130219Abstract: The present application provides a composition comprising periodates or persulfates for extracting nucleic acid from a microorganism, and a corresponding method of using the composition for nucleic acid extraction. The composition and method are particularly useful in extracting nucleic acid from microorganisms that are generally resistant to standard nucleic extraction techniques, such as, one or more species of the Mycobacterium genus, one or more species of the M. tuberculosis complex, MDR strains of M. tuberculosis, one or more species of Clostridium, one or more species of Bacillus, and other microorganisms with hardy cell walls.Type: ApplicationFiled: April 10, 2015Publication date: May 11, 2017Applicant: DNA GENOTEK INC.Inventors: H. Chaim BIRNBOIM, Olle Maarten DE BRUIN
-
Publication number: 20170130220Abstract: Aspects herein relate to composition, and related methods, for isolating and assembling DNA molecules without intermediate cloning steps.Type: ApplicationFiled: September 21, 2016Publication date: May 11, 2017Applicant: Massachusetts Institute of TechnologyInventors: Jonathan William Babb, Shuo Cory Li, Thomas Knight, Ron Weiss
-
Publication number: 20170130221Abstract: This invention relates to compounds, compositions, and methods useful for reducing ?-1 antitrypsin target RNA and protein levels via use of dsRNAs, e.g., Dicer substrate siRNA (DsiRNA) agents.Type: ApplicationFiled: August 25, 2016Publication date: May 11, 2017Inventors: Bob D. Brown, Henryk T. Dudek
-
Publication number: 20170130222Abstract: Methods of administering an oligonucleotide of interest into a cell in vitro or in vivo are described. In the methods, a small organic compound active agent is concurrently administered to the cell in an amount effective to increase the delivery of the oligonucleotide into the cell, and/or increase the activity of said oligonucleotide in the cell. Compositions useful for carrying out the method are also described.Type: ApplicationFiled: June 26, 2015Publication date: May 11, 2017Inventors: Rudolph JULIANO, William P. JANZEN, Joseph A. MADDRY, Canhong CAO, Xin MING, Bing YANG
-
Publication number: 20170130223Abstract: The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.Type: ApplicationFiled: January 13, 2017Publication date: May 11, 2017Inventor: Rakhee S. Gupte
-
Publication number: 20170130224Abstract: The present invention provides gapped oligomeric compounds. More particularly the gapped oligomeric compounds provided herein comprise at least one modified internucleoside linkage in the gap region. Such gapped oligomeric compounds have one or more improved properties such as selectivity, potency, improved toxicity profile and or improved proinflammatory profile. Certain such oligomeric compounds are useful for hybridizing to a complementary nucleic acid, including but not limited, to nucleic acids in a cell. In certain embodiments, hybridization results in modulation of the amount activity or expression of the target nucleic acid in a cell.Type: ApplicationFiled: January 16, 2017Publication date: May 11, 2017Applicant: Ionis Pharmaceuticals, Inc.Inventors: Michael Oestergaard, Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
-
Publication number: 20170130225Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.Type: ApplicationFiled: June 27, 2016Publication date: May 11, 2017Inventors: Sergei Gryaznov, Krisztina Pongracz
-
Publication number: 20170130226Abstract: The invention relates to novel aptamers, in particular aptamers which are capable of binding to EGFR. The invention also relates to cancer cell binding complexes comprising said aptamers and the use of said cancer cell binding complexes in the treatment of cancer.Type: ApplicationFiled: June 23, 2015Publication date: May 11, 2017Inventors: Bradley HALL, Paul HATALA
-
Publication number: 20170130227Abstract: The invention relates to a nucleic acid aptamer with the capability of binding specifically to and inhibiting TLR-4, to a complex comprising said aptamer and a functional group, as well as to pharmaceutical compositions thereof. The invention also relates to uses and methods for detecting TLR-4 and to uses and methods for inhibiting TLR-4. Finally, the invention also relates to an aptamer for use in manufacturing a drug for the treatment of a pathology characterized by an increase in expression of TLR4 and/or an increase in activation of TLR-4.Type: ApplicationFiled: June 24, 2015Publication date: May 11, 2017Inventors: Ignacio LIZASOAIN HERNANDEZ, Victor Manuel GONZALEZ MUÑOZ, Geronimo FERNANDEZ GOMEZ-CHACON, Maria Angeles MORO SANCHEZ, Maria Elena MARTIN PALMA, Ana MORAGA YEBENES
-
Publication number: 20170130228Abstract: The present invention includes compositions and methods of inhibiting or activating TLR7 signaling. In one aspect, a composition includes an inhibitor of TLR7 signaling is described, where the inhibitor of TLR7 signaling is a TLR7 inhibitory oligonucleotide, a TLR7 antibody, or a TLR7 antagonist. In another aspect, a composition and method are described for preventing and treating viral infection of a T cell in a subject. Methods for decreasing T cell proliferation by administering a composition with a TLR7 ligand or agonist or inducing T cell anergy in a subject by stimulating T cells with a TLR7 ligand or agonist are also described.Type: ApplicationFiled: June 18, 2015Publication date: May 11, 2017Inventors: Margarita DOMINGUEZ-VILLAR, David A. HAFLER
-
Publication number: 20170130229Abstract: The disclosure provides methods and compositions for inhibiting or treating influenza comprising an miRNA that promotes Bcl-2 inhibition or mTOR/PI3K activation. The disclosure provides miR-16 and/or miR-100 nucleic acids and mimetics for the treatment or inhibition of influenza infection.Type: ApplicationFiled: June 18, 2015Publication date: May 11, 2017Inventors: Shou-Wei Ding, Yang Yang Li
-
Publication number: 20170130230Abstract: PVT1 exon 9 is overexpressed in aggressively tumorigenic prostate cancer cell lines and prostate tumor tissues. This exon provides a diagnostic tool for the detection and monitoring of aggressive prostate cancer. Several small interfering ribonucleic acids (siRNAs) are disclosed that are useful for treating prostate cancer.Type: ApplicationFiled: November 7, 2016Publication date: May 11, 2017Inventors: Olorunseun O. Ogunwobi, Adeodat Ilboudo, Chunxiao Ying
-
Publication number: 20170130231Abstract: The present invention relates to a novel siRNA, and a high-efficiency double-stranded oligo RNA structure containing the same, and a nanoparticle containing the high-efficiency double-stranded oligo RNA structure. The double-stranded oligo RNA structure has a structure in which a hydrophilic material and a hydrophobic material are conjugated to both ends of a double-stranded oligo RNA (siRNA) via a simple covalent bond or linker-mediated covalent bond in order to be efficiently delivered into cells, and may be converted into a nanoparticle form in an aqueous solution by hydrophobic interactions of double-stranded oligo RNA structures. It is preferable that the siRNA contained in the double-stranded oligo RNA structure is an siRNA specific for fibrosis or respiratory disease-related gene, particularly, amphiregulin or stratifin.Type: ApplicationFiled: April 6, 2015Publication date: May 11, 2017Inventors: Jeiwook CHAE, Pyoung Oh YOON, Boram HAN, Mi Na KIM, Youngho KO, Han Oh PARK
-
Publication number: 20170130232Abstract: Methods for inducing non-clonal immortalization of normal epithelial cells by directly targeting the two main senescence barriers encountered by cultured epithelial cells. In finite lifespan pre-stasis human mammary epithelial cells (HMEC), the stress-associated stasis barrier was bypassed, and in post-stasis HMEC, the replicative senescence barrier, a consequence of critically shortened telomeres, was bypassed. Early passage non-clonal immortalized lines exhibited normal karyotypes. Methods of efficient HMEC immortalization, in the absence of “passenger” genomic errors, should facilitate examination of telomerase regulation and immortalization during human carcinoma progression, methods for screening for toxic and environmental effect on progression, and the development of therapeutics targeting the process of immortalization.Type: ApplicationFiled: September 2, 2016Publication date: May 11, 2017Applicants: The Regents of the University of California, The Arizona Board of Regents on Behalf of the University of ArizonaInventors: Martha R. Stampfer, James C. Garbe, Lukas Vrba, Bernard W. Futscher
-
Publication number: 20170130233Abstract: The invention relates to a yeast strain and to a method for microbial production of pentacyclic triterpenes and/or triterpenoids in yeast. More particularly, the invention relates to a modified yeast strain for production of pentacyclic triterpenoids comprising at least one copy of a gene for encoding an oxidosqualene cyclase, at least one copy of a gene for encoding an NADPH-cytochrome P450 reductase and/or at least one copy of a gene for encoding a cytochrome P450 monooxygenase.Type: ApplicationFiled: February 6, 2015Publication date: May 11, 2017Inventors: Christine Lang, Anna Lewandowski
-
Publication number: 20170130234Abstract: The invention provides a non-naturally occurring microbial organism having an adipate, 6-aminocaproic acid or caprolactam pathway. The microbial organism contains at least one exogenous nucleic acid encoding an enzyme in the respective adipate, 6-aminocaproic acid or caprolactam pathway. The invention additionally provides a method for producing adipate, 6-aminocaproic acid or caprolactam. The method can include culturing an adipate, 6-aminocaproic acid or caprolactam producing microbial organism, where the microbial organism expresses at least one exogenous nucleic acid encoding an adipate, 6-aminocaproic acid or caprolactam pathway enzyme in a sufficient amount to produce the respective product, under conditions and for a sufficient period of time to produce adipate, 6-aminocaproic acid or caprolactam.Type: ApplicationFiled: June 16, 2016Publication date: May 11, 2017Inventors: Anthony P. BURGARD, Priti PHARKYA, Robin E. OSTERHOUT
-
Publication number: 20170130235Abstract: The present invention relates to a method for fine-tuning gene expression levels using a synthetic regulatory sRNA in a prokaryotic cell. The present invention can simultaneously, easily, and quickly apply various target gene combinations to various strains without gene deletion through the synthetic regulatory sRNA for regulating gene expression and is therefore very suitable for measuring the metabolizability of each strain and selecting an optimum strain. In addition, the method has the advantages of easily and quickly selecting a target gene for the inhibition of gene expression and expressing the gene thus selected to a desired degree and thus can be used in producing recombinant strains for the efficient production of various metabolites and establishing a method for the efficient production and is therefore very useful.Type: ApplicationFiled: June 11, 2014Publication date: May 11, 2017Applicant: Korea Advanced Institute of Science and TechnologyInventors: Sang Yup Lee, Minho Roh, Seung Min Yoo
-
Publication number: 20170130236Abstract: The subject invention pertains to a method of rapidly transforming a plant with a gene of interest. The method of the current invention comprises the steps of a) preparing a bacterial culture, wherein the bacterial culture comprises a vector containing the gene of interest, b) producing a plant cell suspension culture from the plant, c) contacting the plant cell suspension culture with the bacterial culture to produce a plant cell transformed with the gene of interest from the plant cell suspension culture, and e) producing a plant from the plant cell transformed with the gene of interest. The method of the current invention can be designed for a high throughput transformation and screening of a plant with a plurality of genes of interest and screening the plants to identify and obtain plants having desirable characteristics.Type: ApplicationFiled: June 2, 2015Publication date: May 11, 2017Inventors: C. NEAL STEWART, Jr., JONATHAN D. WILLIS, JASON BURRIS, MITRA MAZAREI
-
Publication number: 20170130237Abstract: Transfection of plant cells with dsRNA through foliar application encounters cuticle, cell wall and plasmalemma three major barriers. We developed cationic polymer and sugar based formulations and protocols that can effectively deliver dsRNA into plant cells resulted in gene silencing. This disclosure covers the novel methods to deliver dsRNA into plant suspension cells with ‘one step’ treatment and plant foliar cells with ‘one step’ topical application.Type: ApplicationFiled: June 24, 2015Publication date: May 11, 2017Applicant: Monsanto Technology LLCInventors: Michael Bennett, Bill L. Hendrix, Alberto landolino, Yao Luo, Wei Zheng
-
Publication number: 20170130238Abstract: The present invention provides an innovate method and device for depositing coated particles to prepare sample cartridges for use in a gene gun.Type: ApplicationFiled: November 3, 2016Publication date: May 11, 2017Inventors: Amanda R. Edwards, John H. Verruto
-
Publication number: 20170130239Abstract: The present invention relates to a mutant, non-naturally occurring or transgenic tobacco plant cell comprising: (i) a polynucleotide comprising, consisting or consisting essentially of a sequence encoding a functional nicotine N-demethylase and having at least 95% sequence identity to SEQ ID NO:2; (ii) a polypeptide encoded by the polynucleotide set forth in (i); (iii) a polypeptide comprising, consisting or consisting essentially of a sequence encoding a nicotine N-demethylase and having at least 95% sequence identity to SEQ ID NO:3; or (iv) a construct, vector or expression vector comprising the isolated polynucleotide set forth in (i), and wherein the expression or activity of said nicotine demethylase is reduced as compared to a control tobacco plant cell in which the expression or activity of said nicotine demethylase has not been reduced.Type: ApplicationFiled: May 7, 2015Publication date: May 11, 2017Inventors: Verena Liedschulte, Simon Goepfert, Lucien Bovet, Nicolas Sierro
-
Publication number: 20170130240Abstract: The present invention is directed to plants that display an improved oil quantity phenotype or an improved meal quality phenotype due to altered expression of an IMQ nucleic acid. The invention is further directed to methods of generating plants with an improved oil quantity phenotype or improved meal quality phenotype.Type: ApplicationFiled: January 18, 2017Publication date: May 11, 2017Applicant: Agrigenetics, Inc.Inventors: John P. Davies, Hein Tsoeng (Medard) Ng, D. Ry Wagner
-
Publication number: 20170130241Abstract: A plant type related protein, and a coding gene and an application thereof are provided. The protein is: (a) a protein consisting of the amino acid sequence of SEQ ID NO: 1; (b) a SEQ ID NO: 1-derived protein having substitution, deletion, and/or addition of an amino acid residue on the sequence of SEQ ID NO: 1, and related to the plant type and/or inactivation of a plant brassinolide type, or (c) a protein having more than 80% homology to the sequence of SEQ ID NO: 1 and related to a plant type and inactivation of a plant brassinolide type. The protein and its coding gene have very important value in improving crop production, improving the visual enjoyability of a green plant, implementing simple cultivation of a plant and improving the breeding efficiency, and has a broad prospective in genetic improvement of a plant, new variety cultivation and an application.Type: ApplicationFiled: April 9, 2013Publication date: May 11, 2017Applicant: Cotton Research Institute, Chinese Academy of Agricultural SciencesInventors: Fuguang Li, Zuoren Yang, Chaojun Zhang, Yufen Wang, Zhixia Wu, Chuanliang Liu, Xueyan Zhang, Ye Wang, Fenglian Li, Qianhua Wang, Wengiang Qin, Depei Kong
-
Publication number: 20170130242Abstract: Isolated polynucleotides and polypeptides, and recombinant DNA constructs useful for conferring improved nitrogen use efficiency and/or drought stress tolerance; compositions (such as plants or seeds) comprising these recombinant DNA constructs; and methods utilizing these recombinant DNA constructs are disclosed. The recombinant DNA constructs comprise a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotides encode abiotic stress tolerance polypeptides.Type: ApplicationFiled: July 2, 2015Publication date: May 11, 2017Applicant: PIONEER OVERSEAS CORPORATIONInventors: GUIHUA LU, YANG GAO, CONG LI, JUNHUA LIU, GUANFAN MAO, WEI WANG, XIPING WANG
-
Publication number: 20170130243Abstract: This disclosure concerns nucleic acid molecules and methods of use thereof for control of insect pests through RNA interference-mediated inhibition of target coding and transcribed non-coding sequences in insect pests, including coleopteran and/or hemipteran pests. The disclosure also concerns methods for making transgenic plants that express nucleic acid molecules useful for the control of insect pests, and the plant cells and plants obtained thereby.Type: ApplicationFiled: September 26, 2016Publication date: May 11, 2017Inventors: Kenneth E. Narva, Sarah Worden, Meghan L.F. Frey, Murugesan Rangasamy, Kanika Arora, Balaji Veeramani, Premchand Gandra, Elane Fishilevich, Chaoxian Geng, Andreas Vilcinskas, Eileen Knorr
-
Publication number: 20170130244Abstract: The present invention provides for functional chimeric gene regulatory units capable of driving strong and sustained heterologous gene expression.Type: ApplicationFiled: June 17, 2015Publication date: May 11, 2017Inventors: Yuansheng YANG, Cheng Leong Steven HO, Shiyi GOH FANG
-
Publication number: 20170130245Abstract: The present invention relates to viral vectors and methods of their production and use.Type: ApplicationFiled: June 9, 2015Publication date: May 11, 2017Inventors: Robert KOTIN, Jinzhao HOU, James MCLAUGHLIN
-
Publication number: 20170130246Abstract: Compounds of the formula (Z)x wherein: each Z is independently selected from 2?-deoxythymidinyl moiety, 2?-deoxyadenosinyl moiety, and a 2?-deoxycytidinyl moiety, x is an integer from 5-20, wherein said 2?-deoxythymidinyl moieties are connected by thiophosphate triester linkages, and 3-12 of said thiophosphate triester linkages being positively charged linkages of the formula: where n is an integer from 2 to 6; and the remainder of the thiophosphate triester linkages are neutral linkages of the formula: provided that when x is 5-6, the number of positively charged linkages is 3, when x is 7-8, the number of positively charged linkages is 3-4, when x is 9-12, the number of positively charged linkages is 3-10, and when x is 13-20, the number of positively charged linkages is 4-12.Type: ApplicationFiled: September 14, 2016Publication date: May 11, 2017Inventors: Serge L. BEAUCAGE, Harsh V. JAIN
-
Publication number: 20170130247Abstract: Provided herein are improved compositions and methods for the directed control of gene expression.Type: ApplicationFiled: September 30, 2016Publication date: May 11, 2017Inventors: Jill M. Dowen, Zi Peng Fan, Denes Hnisz, Tong Ihn Lee, Richard A. Young
-
Publication number: 20170130248Abstract: The present invention relates to a cell for producing acyl glycinates wherein the cell is genetically modified to comprise at least a first genetic mutation that increases the expression relative to the wild type cell of an amino acid-N-acyl-transferase, at least a second genetic mutation that increases the expression relative to the wild type cell of an acyl-CoA synthetase, and at least a third genetic mutation that decreases the expression relative to the wild type cell of at least one enzyme selected from the group consisting of an enzyme of the glycine cleavage system, glycine hydroxymethyltransferase (GlyA) and threonine aldolase (LtaE).Type: ApplicationFiled: April 28, 2015Publication date: May 11, 2017Applicant: Evonik Degussa GmbHInventors: LIV REINECKE, STEFFEN SCHAFFER, KATRIN GRAMMANN, MAIK OLFERT, NICOLE DECKER, NILS ARTO, HANS-GEORG HENNEMANN
-
Publication number: 20170130249Abstract: The present invention relates to a method for producing chiral ?-nitro alcohol compounds. The invention relates in particular to an (R)-selective cupin-nitroaldolase, which enantioselectively can catalyze the Henry reaction, wherein an aldehyde or ketone compound is converted to the corresponding ?-nitro alcohol compound in the presence of a nitroalkane compound and a cupin-nitroaldolase.Type: ApplicationFiled: June 12, 2015Publication date: May 11, 2017Inventors: Kerstin Steiner, Mandana Gruber, Romana Wiedner, Helmut Schwab
-
Publication number: 20170130250Abstract: Methods that may be used for the manufacture of the chemical compound (S)-norcoclaurine, (S)-norlaudanosoline, and (S)-norcoclaurine or [S]-norlaudanosoline synthesis intermediates are provided. (S)-Norcoclaurine, (S)-norlaudanosoline, and (S)-norcoclaurine or (S)-norlaudanosoline synthesis intermediates are useful as precursor products in the manufacture of certain medicinal agents.Type: ApplicationFiled: June 12, 2015Publication date: May 11, 2017Inventor: Peter James Facchini
-
Publication number: 20170130251Abstract: A fermentation process for fermenting a starch hydrolysate containing 60-98 weight percent of glucose based on total carbohydrate and 0.3-5% weight percent of isomaltose based on total carbohydrate to a non-ethanol fermentation product is carried out. The method comprises: a) forming a fermentation broth containing the starch hydrolysate and a genetically modified microorganism containing i) an exogenous gene encoding transporter capable of transporting isomaltose ii) an exogenous gene encoding an enzyme capable of converting isomaltose to glucose; and b) fermenting the starch hydrolysate in the fermentation broth to produce a non-ethanol fermentation product. This fermentation process may be carried out as a single step fermentation or a batch process. The genetically modified microorganism may contain an exogenous gene encoding an enzyme that catalyzes the formation of a product other than ethanol.Type: ApplicationFiled: June 18, 2015Publication date: May 11, 2017Inventors: Keith M. Brady, Christopher K. Miller
